You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Med., 04 May 2022

Sec. Rheumatology

Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.923790

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

  • 1. Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy

  • 2. Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy

  • 3. Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy

  • 4. Dia.Pro, Diagnostic Bioprobes Srl, Milan, Italy

  • 5. Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

  • 6. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

  • 7. Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy

Article metrics

View details

961

Views

543

Downloads

In the original article, an author name was incorrectly spelled as “Alessandra Bandiera.” The correct spelling is “Alessandra Bandera.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

seroprevalence, SARS-CoV-2, humoral response, rheumatic musculoskeletal diseases, disease-modifying anti-rheumatic drugs, risk of infection, COVID-19

Citation

Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandera A, Gori A, Abrignani S, Grifantini R and Caporali R (2022) Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Front. Med. 9:923790. doi: 10.3389/fmed.2022.923790

Received

19 April 2022

Accepted

20 April 2022

Published

04 May 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

9 - 2022

Updates

Copyright

*Correspondence: Ennio Giulio Favalli

†These authors have contributed equally to this work

This article was submitted to Rheumatology, a section of the journal Frontiers in Medicine

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics